Wave Life Sciences Ltd.

Position: small long, sized for a binary readout. WVE-006 cleared the 11 µM protective AAT threshold at 200 mg multidose in September 2025 — 11.9 µM total AAT, 7.2 µM corrected M-AAT, 60.3% Z-AAT reduction (n=8) C004 — the same bar Korro's LNP construct missed before terminating REWRITE for "business decision reasons" C007. Wave guides that data "support monthly or less frequent subcutaneous dosing" C001. Two scenarios drive the trade.

The bull case rests on the 400 mg cohort holding above 11 µM with Z-AAT reduction comparable to the 60% seen at 200 mg. That combination supports a less-frequent dosing label and an FDA accelerated-approval pathway on AAT biomarkers — the same pathway Beam-302 is pursuing.

The bear case is BEAM-302. Beam's 60 mg single-dose cohort produced 16.1 µM total AAT, 94% corrected M-AAT, and 84% Z-AAT reduction at 5–12 month follow-up C005C006. Beam selected 60 mg as the pivotal dose in March 2026 and intends to enroll roughly 50 additional patients in pivotal development in H2 2026. The simple thesis "GalNAc clears 11 µM where LNP didn't" therefore needs qualification: a different LNP-delivered base editor cleared 11 µM at a single dose, and cleared it harder than WVE-006's multidose result.

Catalyst: Mon May 18, 2026, ATS late-breaking oral C002. Cash runway into 3Q 2028 C009 means the company has the optionality to run multiple cohorts, but the ATS print is the binary that prices the trade.

Wave's Q1 2026 earnings press release (8-K Exhibit 99.1, filed 2026-04-28) previews the readout. Bolno (CEO): "In May, we expect to highlight data from our RestorAATion-2 trial, including results from our less frequent, 400 mg monthly dose and 600 mg single dose cohorts." C001 The acceptance of the late-breaking oral session was disclosed earlier in 2026 C002. The trial registry record at NCT06405633 confirms an open-label, sequential, non-randomized Phase 1b/2a in 24 PiZZ AATD participants, dosed at three escalating levels C003.

What we already know from the 200 mg multidose cohort (n=8, disclosed 2025-09-03) C004:

The multidose cohort cleared the 11 µM protective threshold; the single-dose cohort did not. The doubling of M-AAT from single to multiple doses (4.8 → 7.2 µM, p=0.012) is the data point that supports a monthly dosing label.

The May 18 disclosure will test three things at once: whether 400 mg monthly multidose maintains or exceeds the 200 mg multidose biomarker, whether 600 mg single-dose extends durability or peak AAT meaningfully, and whether the safety profile holds across higher doses. Wave's framing — "monthly or less frequent dosing" — implicitly raises the bar: anything worse than monthly compromises the convenience differentiator that the regained-rights de-partnering argument rests on.

WVE-006 is "a GalNAc-conjugated, A-to-I RNA editing oligonucleotide" using Wave's AIMer technology C004. The mechanism, in plain terms: the oligonucleotide pairs with mutant SERPINA1 mRNA at the Z-mutation site, recruits the endogenous ADAR enzyme to deaminate the offending adenosine to inosine (which the ribosome reads as guanosine), and converts a transcript that would have produced misfolded Z-AAT protein into one producing wild-type M-AAT. The result is dynamic, regulated production of functional AAT under the body's existing transcriptional controls — observable in the data via the 20+ µM AAT spike during one patient's kidney-stone-induced acute phase response C010. The same patient's baseline AAT was sub-quantification before treatment.

This dynamic-regulation property differentiates WVE-006 from augmentation therapy (a fixed weekly IV dose of exogenous protein) and from gene editing (a one-time DNA correction without endogenous regulation). It is the closest mechanism on the market to recapitulating the heterozygote PiMZ phenotype, where the patient produces normal M-AAT alongside the pathogenic Z-AAT and is largely protected from severe disease. Rennard (Univ. Nebraska, in Wave's Sept 2025 release): "RNA editing resulted in the endogenous production of M protein in ZZ individuals." C004

GalNAc conjugation targets hepatocytes — the relevant cell type for both lung disease (AAT is liver-secreted) and the AATD-associated liver disease (which augmentation therapy does not address). The subcutaneous route, monthly or less frequent, is the convenience asset.

Three RNA-editing programs targeted PiZZ AATD in clinic in 2025–2026. The class scorecard is now public.

Sources: WVE-006 from GlobeNewswire 2025-09-03 C004; BEAM-302 from beamtx.com press release 2026-03-25 C005 and Marketchameleon's tabulated extract C006; KRRO-110 from Korro Q3 2025 release 2025-11-12 C007 and ClinicalTrials.gov NCT06677307 C008.

What the comparison says. KRRO-110's failure was not subtle. Korro itself wrote that the program "fell short of the protective 11 µM threshold," explicitly framing 11 µM as the bar that mattered. Corporate response was a 34% workforce reduction, the CMO's resignation, a strategic pivot to a GalNAc construct (a remarkable concession to Wave's chemistry), and termination of REWRITE C007C008. Korro's pivot to GalNAc removes one comparator and validates Wave's delivery choice. That is the cleanest version of the original delivery-edge thesis.

But BEAM-302 complicates the story. Beam's LNP-delivered base editor cleared the 11 µM threshold by 5 µM at a single dose that produces 94% corrected M-AAT — a fundamentally different efficacy ceiling than RNA editing achieves C005. Wave's data show roughly 64% M-AAT at the 200 mg multidose, less than Beam's 94% at 60 mg single dose, and Wave requires repeat dosing to reach the threshold. The differentiator Wave emphasizes — that WVE-006 "avoids delivery with LNPs and collateral bystander edits and indels" (Bolno, 2026-04-28) C001 — is real but contestable. Beam's pivotal dose follow-up has been clean enough through 18 months to support FDA-aligned pivotal development. The "permanence" argument cuts both ways: BEAM-302's correction is a single-shot durable fix, while WVE-006 requires monthly dosing for life.

The class verdict, four months before the catalyst:

• GalNAc beats Korro's LNP: confirmed (KRRO-110 terminated, Korro pivoting to GalNAc).
• GalNAc beats Beam's LNP base editor: not at single-dose efficacy, not at peak M-AAT, not at durability. The defensible WVE-006 claim is "comparable durable AAT level with a non-permanent, non-DNA-modifying mechanism on a monthly subcutaneous dosing schedule." Defensible, but a step down from "best-in-class."

Wave reported its Q1 2026 10-Q on 2026-04-28 C009.

The runway claim — "into 3Q 2028" — implies roughly nine quarters of cash from a Q1 2026 base, consistent with a ~$60M quarterly burn against $544M plus the upside from GSK milestones not included in runway guidance. The $2.8B in potential GSK milestones across the broader collaboration (now expanded to a fourth program) is non-cash optionality rather than runway C010.

PiZZ AATD prevalence is poorly counted. Estimates range:

• Indirect Hardy-Weinberg estimate (US): ~33,000 PiZZ individuals C011.
• US population-based newborn screening: ~70,000 PiZZ in US (1/4,455 frequency) C011.
• Wave's stated population (US + Europe combined): "200,000 individuals" C004.

Wave's 200,000 figure is plausibly correct as a combined US+EU number under the higher prevalence estimates (e.g., Sweden 1/1,550), but it is at the upper end of published ranges. We treat 100,000–200,000 as a defensible range, not 200,000 as a verified ceiling.

Standard of care: Weekly intravenous augmentation therapy with plasma-derived AAT — Prolastin-C, Glassia, Aralast NP, Zemaira. The ATS/ERS guideline cites the 11 µM serum AAT level as the protective threshold and as the eligibility criterion for augmentation C012. The Canadian Thoracic Society 2025 guideline: "Eligibility for augmentation therapy requires... a SERPINA1 genotype linked to deficiency, and a serum A1AT level <11 umol/L." C013

The augmentation market generated "over $1.4 billion in worldwide sales (2023)" per Wave's framing C004. Annual cost per US patient on augmentation: roughly $90,000–$127,000 across published payer data C014. The augmentation market is a 50-year-old plasma-derived therapy class with no RCT-validated mortality benefit (RAPID trial, 2015, showed slowed CT-density loss but did not establish clinical-outcome benefit) C015. No therapy is approved for AATD-associated liver disease, where roughly 25% of PiZZ deaths originate C011. This is the white-space WVE-006 occupies.

1. BEAM-302 commercial collision. Beam's pivotal cohort begins H2 2026 with FDA accelerated-approval alignment on AAT biomarkers — the same pathway Wave intends to pursue with mid-2026 regulatory feedback C001. A first-mover BLA from Beam in 2027–2028, even with restrictions, captures the commercial premium of "best-in-class" status. Wave's defensive position requires winning on dosing convenience (monthly SC vs. one-time IV), regulatory permanence concerns (accelerated approval with confirmatory commitments often penalizes irreversible mechanisms), and possibly cost. None of these are decisive.

2. The 400 mg readout. The May 18 ATS data must show that 400 mg monthly multidose either matches or exceeds 200 mg multidose's 11.9 µM total AAT and 7.2 µM M-AAT C004. A flat or worse readout — e.g., 400 mg producing similar AAT levels as 200 mg with no durability advantage — disqualifies the "less than monthly" framing and reads as biological saturation rather than dose response.

3. TEAEs at 600 mg. The 200 mg cohort had no SAEs. The 400 mg single-dose cohort, similarly clean. The 600 mg single dose is the first WVE-006 cohort at this exposure level. GalNAc oligonucleotides have generally clean safety profiles in other targets (Givosiran, Lumasiran, Inclisiran), but the dose-response for ADAR-recruiting AIMers in human ZZ tissue at 600 mg is not previously characterized.

4. n=24 trial. RestorAATion-2 estimated enrollment is 24 across three sequential cohorts C003. Statistical confidence on biomarker durability and safety is limited at this n. The pivotal program will need substantially larger sample sizes (Beam's plan: ~50 additional patients in pivotal expansion).

5. Rare disease commercial execution. Wave has never marketed a drug. WVE-N531 (DMD) is mid-Phase-2; WVE-007 (obesity) is Phase 1. The infrastructure to launch a rare-disease therapy — patient finding, payer engagement, complex distribution — is not yet built. The $2.8B GSK milestone optionality on the discovery collaboration partly compensates C010.

6. GSK reversion ambiguity. The disclosure does not explain the deliberation. GSK's commitment to continue and expand the broader research collaboration is the strongest contemporaneous evidence that this was not a quality-driven walk-away. But the asymmetry of disclosure — what GSK said, what GSK did not say — is itself a risk factor.